Age, Biography and Wiki
Chris Abell (Christopher Abell) was born on 11 November, 1957 in United Kingdom, is a British biological chemist (1957–2020). Discover Chris Abell's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 62 years old?
Popular As |
Christopher Abell |
Occupation |
N/A |
Age |
62 years old |
Zodiac Sign |
Scorpio |
Born |
11 November 1957 |
Birthday |
11 November |
Birthplace |
N/A |
Date of death |
26 October, 2020 |
Died Place |
N/A |
Nationality |
United Kingdom
|
We recommend you to check the complete list of Famous People born on 11 November.
He is a member of famous with the age 62 years old group.
Chris Abell Height, Weight & Measurements
At 62 years old, Chris Abell height not available right now. We will update Chris Abell's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
Physical Status |
Height |
Not Available |
Weight |
Not Available |
Body Measurements |
Not Available |
Eye Color |
Not Available |
Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
Family |
Parents |
Not Available |
Wife |
Not Available |
Sibling |
Not Available |
Children |
Not Available |
Chris Abell Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Chris Abell worth at the age of 62 years old? Chris Abell’s income source is mostly from being a successful . He is from United Kingdom. We have estimated Chris Abell's net worth, money, salary, income, and assets.
Net Worth in 2024 |
$1 Million - $5 Million |
Salary in 2024 |
Under Review |
Net Worth in 2023 |
Pending |
Salary in 2023 |
Under Review |
House |
Not Available |
Cars |
Not Available |
Source of Income |
|
Chris Abell Social Network
Timeline
Christopher Abell (11 November 1957 – 26 October 2020 ) was a British biological chemist who was a professor of biological chemistry at the Yusuf Hamied Department of Chemistry and Todd-Hamied Fellow of Christ's College, Cambridge.
Abell was educated at St John's College, Cambridge, gaining an Bachelor of Arts degree in Natural Sciences in 1979 followed by PhD on the topic of polyketide biosynthesis for research supervised by James Staunton in 1982.
In 1981, he married Katherine Abell, who worked with him at the department of chemistry in Cambridge; they had a son.
Abell held a research fellowship in the laboratory of David E. Cane at Brown University, Providence, USA, studying terpene biosynthesis (1982–83).
In 1984, Abell joined the department of chemistry of the University of Cambridge, successively holding the positions of demonstrator, lecturer and reader in chemical biology, and becoming professor in biological chemistry in 2002.
He held visiting professorships at the Australian National University in Canberra, University of Santiago de Compostela, University of Canterbury, Christchurch, and the Paul Sabatier University, Toulouse.
He was a fellow of Christ's College, Cambridge, from 1986; and was the college's Todd-Hamied Fellow.
His awards include the Imperial Chemical Industries (ICI) Prize in Organic Chemistry in 1992, the Hickinbottom Award of the Royal Society of Chemistry, and a Yamada Science Foundation Award.
In 1999, he co-founded Astex Technology Ltd, which uses fragment-based drug discovery technology to discover cancer therapeutics.
In 2001, he co-founded Akubio, which developed biosensors for detecting bacteria and viruses; it was acquired by Inverness Medical Innovations in 2008.
In 2008 he was the MIT Novartis Lecturer, and in 2011 was a BIC International Fellow at the University of Canterbury, Christchurch, New Zealand.
In 2010, he co-founded Sphere Fluidics to develop microdroplet technology.
In 2012 he co-founded Aqdot, a company developing a new microencapsulation technology.
He was elected a Fellow of the Academy of Medical Sciences (FMedSci) in 2012 and a Fellow of the Royal Society (FRS) in 2016.
In 2013 he was appointed the first director of postdoctoral affairs at the University of Cambridge, and in 2016 was appointed pro-vice-chancellor for research.
Abell published over 200 papers.
His research interests include vitamin and amino acid biosynthesis as targets for the rational design of antimicrobials; fragment-based approaches to enzyme inhibition; bacterial and plant riboswitches; reactions in microdroplets; and biological nanotechnology.
Abell was the co-founder of several companies.
On his 2016 election to the Royal Society, Abell's research was described as having "changed the face of drug discovery."
He died suddenly on 26 October 2020.